CALIFORNIA NANOTECHNOLOGIES (CNO.CA) Stock Fundamental Analysis
Canada - TSX Venture Exchange - TSX-V:CNO - CA1304921010 - Common Stock
0.35 CAD
+0.01 (+1.45%)
CNO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 21 industry peers in the Machinery industry. While CNO seems to be doing ok healthwise, there are quite some concerns on its profitability. CNO is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
CNO had negative earnings in the past year.
CNO had a positive operating cash flow in the past year.
In multiple years CNO reported negative net income over the last 5 years.
In the past 5 years CNO always reported a positive cash flow from operatings.
1.2 Ratios
CNO has a Return On Assets of -21.51%. This is in the lower half of the industry: CNO underperforms 66.67% of its industry peers.
The Return On Equity of CNO (-39.65%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.51% | ||
| ROE | -39.65% | ||
| ROIC | N/A |
ROA(3y)7%
ROA(5y)3.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CNO's Operating Margin has improved in the last couple of years.
CNO has a Gross Margin of 69.19%. This is amongst the best in the industry. CNO outperforms 95.24% of its industry peers.
In the last couple of years the Gross Margin of CNO has grown nicely.
The Profit Margin and Operating Margin are not available for CNO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.19% |
OM growth 3Y4.57%
OM growth 5Y69.99%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.75%
GM growth 5Y3.23%
2. Health
2.1 Basic Checks
CNO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CNO has been increased compared to 1 year ago.
CNO has more shares outstanding than it did 5 years ago.
CNO has a worse debt/assets ratio than last year.
2.2 Solvency
CNO has an Altman-Z score of 2.91. This is not the best score and indicates that CNO is in the grey zone with still only limited risk for bankruptcy at the moment.
CNO has a better Altman-Z score (2.91) than 76.19% of its industry peers.
The Debt to FCF ratio of CNO is 4.46, which is a neutral value as it means it would take CNO, 4.46 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.46, CNO is in the better half of the industry, outperforming 76.19% of the companies in the same industry.
CNO has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.49, CNO perfoms like the industry average, outperforming 57.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | 4.46 | ||
| Altman-Z | 2.91 |
ROIC/WACCN/A
WACC9.49%
2.3 Liquidity
CNO has a Current Ratio of 1.19. This is a normal value and indicates that CNO is financially healthy and should not expect problems in meeting its short term obligations.
CNO has a Current ratio of 1.19. This is in the lower half of the industry: CNO underperforms 76.19% of its industry peers.
CNO has a Quick Ratio of 1.19. This is a normal value and indicates that CNO is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.19, CNO is in the better half of the industry, outperforming 76.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.19 | ||
| Quick Ratio | 1.19 |
3. Growth
3.1 Past
The earnings per share for CNO have decreased strongly by -477.78% in the last year.
CNO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -17.79%.
CNO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 49.59% yearly.
EPS 1Y (TTM)-477.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.82%
Revenue 1Y (TTM)-17.79%
Revenue growth 3Y79.21%
Revenue growth 5Y49.59%
Sales Q2Q%-48.76%
3.2 Future
CNO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 103.27% yearly.
Based on estimates for the next years, CNO will show a very negative growth in Revenue. The Revenue will decrease by -10.39% on average per year.
EPS Next Y100%
EPS Next 2Y103.27%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-41.27%
Revenue Next 2Y-10.39%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CNO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 24.61, CNO is valued on the expensive side.
CNO's Price/Forward Earnings ratio is in line with the industry average.
CNO's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.56.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 24.61 |
4.2 Price Multiples
CNO's Enterprise Value to EBITDA is on the same level as the industry average.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CNO indicates a somewhat cheap valuation: CNO is cheaper than 66.67% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 38.62 | ||
| EV/EBITDA | 114.2 |
4.3 Compensation for Growth
CNO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CNO's earnings are expected to grow with 103.27% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y103.27%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for CNO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:CNO (12/8/2025, 7:00:00 PM)
0.35
+0.01 (+1.45%)
Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners13.73%
Ins Owner ChangeN/A
Market Cap17.54M
Revenue(TTM)4.45M
Net Income(TTM)-939.70K
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 24.61 | ||
| P/S | 2.85 | ||
| P/FCF | 38.62 | ||
| P/OCF | 6.08 | ||
| P/B | 5.36 | ||
| P/tB | 5.37 | ||
| EV/EBITDA | 114.2 |
EPS(TTM)-0.03
EYN/A
EPS(NY)0.01
Fwd EY4.06%
FCF(TTM)0.01
FCFY2.59%
OCF(TTM)0.06
OCFY16.44%
SpS0.12
BVpS0.07
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.51% | ||
| ROE | -39.65% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.19% | ||
| FCFM | 7.39% |
ROA(3y)7%
ROA(5y)3.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)19.86%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y4.57%
OM growth 5Y69.99%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.75%
GM growth 5Y3.23%
F-Score5
Asset Turnover1.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | 4.46 | ||
| Debt/EBITDA | 9.55 | ||
| Cap/Depr | 253.96% | ||
| Cap/Sales | 39.52% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 1711.31% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.19 | ||
| Quick Ratio | 1.19 | ||
| Altman-Z | 2.91 |
F-Score5
WACC9.49%
ROIC/WACCN/A
Cap/Depr(3y)145.85%
Cap/Depr(5y)N/A
Cap/Sales(3y)13.6%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-477.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.82%
EPS Next Y100%
EPS Next 2Y103.27%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-17.79%
Revenue growth 3Y79.21%
Revenue growth 5Y49.59%
Sales Q2Q%-48.76%
Revenue Next Year-41.27%
Revenue Next 2Y-10.39%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-137.85%
EBIT growth 3Y87.4%
EBIT growth 5Y154.28%
EBIT Next Year-67.61%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y66.62%
FCF growth 3Y80.29%
FCF growth 5Y42.36%
OCF growth 1Y667.86%
OCF growth 3Y173%
OCF growth 5Y84.63%
CALIFORNIA NANOTECHNOLOGIES / CNO.CA FAQ
What is the ChartMill fundamental rating of CALIFORNIA NANOTECHNOLOGIES (CNO.CA) stock?
ChartMill assigns a fundamental rating of 3 / 10 to CNO.CA.
Can you provide the valuation status for CALIFORNIA NANOTECHNOLOGIES?
ChartMill assigns a valuation rating of 4 / 10 to CALIFORNIA NANOTECHNOLOGIES (CNO.CA). This can be considered as Fairly Valued.
How profitable is CALIFORNIA NANOTECHNOLOGIES (CNO.CA) stock?
CALIFORNIA NANOTECHNOLOGIES (CNO.CA) has a profitability rating of 3 / 10.
What is the financial health of CALIFORNIA NANOTECHNOLOGIES (CNO.CA) stock?
The financial health rating of CALIFORNIA NANOTECHNOLOGIES (CNO.CA) is 4 / 10.